Tonix Q2 revenue rises sharply on TONMYA launch
TNXP•Outlook
- Company expects to deploy 50 new TONMYA sales representatives by September 2026.
- Tonix expects Phase 2 study of TNX-4800 for Lyme disease to start in Q1 2027.
- Company believes cash resources will fund operations into early Q2 2027.
Result drivers
- TONMYA launch - Net sales of TONMYA nearly tripled quarter-over-quarter, driven by expanded coverage and increased prescriptions.
- Prescription growth - Total prescriptions for TONMYA doubled and refills rose 207% quarter-over-quarter, reflecting broader patient access.
- Sales force expansion - Company is expanding its sales force to support further TONMYA uptake, with 50 new representatives expected to deploy by September.
Key details and analyst coverage
| Metric | Actual |
|---|---|
| Q2 Net Loss | $40.55 mln |
| Q2 Operating Income | -$42.54 mln |
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
The average consensus recommendation for the pharmaceuticals peer group is "buy".
Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp. is $34.00, about 182.6% above its August 7 closing price of $12.03.
